Instituto RosenbuschBUE:ROSE -1.53%39 EBITDA Margin % is 9.24% as of Dec. 2025, which is 18% above its 10-year median of 7.84. GuruFocus rates BUE:ROSE with a GF Score™ of 39/100 and a GF Value™ of ARS61.70 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Instituto Rosenbusch ranks worse than 87.96% on this metric.
Instituto Rosenbusch (BUE:ROSE) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Instituto Rosenbusch EBITDA Margin % Related Terms
Instituto Rosenbusch EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Instituto Rosenbusch's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUE:ROSE vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Instituto Rosenbusch EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Instituto Rosenbusch's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instituto Rosenbusch (BUE:ROSE) has a EBITDA Margin % of 9.24% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Instituto Rosenbusch and its competitors. This is 18% above median its historical median of 7.84. According to the industry distribution chart, Instituto Rosenbusch ranks #840 out of 955 companies in the Drug Manufacturers industry, placing it in the top 88%.
Is Instituto Rosenbusch's EBITDA Margin % too high?
Instituto Rosenbusch's current EBITDA Margin % of 9.24% is 18% above median its 10-year median of 7.84. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Instituto Rosenbusch's value of 9.24% is 25.7% below this industry median. Based on the distribution chart, Instituto Rosenbusch ranks #840 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Instituto Rosenbusch has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Instituto Rosenbusch ranks #840 out of 955 companies for EBITDA Margin %. This places Instituto Rosenbusch in the lower half of its industry. The industry median EBITDA Margin % is 12.44. Instituto Rosenbusch's value of 9.24% is 25.7% below this benchmark. While the company's 10-year median is 7.84 vs. the industry median of 12.44, Instituto Rosenbusch has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Instituto Rosenbusch's current EBITDA Margin % of 9.24% is 25.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Instituto Rosenbusch and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Instituto Rosenbusch's current EBITDA Margin % is 9.24%, which is 18% above median its own 10-year median of 7.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS61.70, compared to a current price of ARS160.50 — trading 160.1% above its estimated fair value. The current EBITDA Margin % is 9.24%, which is 18% above median its 10-year median of 7.84 and 25.7% below the Drug Manufacturers industry median of 12.44. Instituto Rosenbusch's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current EBITDA Margin % is 9.24% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?
Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued.
The current stock price of ARS160.50 is trading 160.1% above its estimated GF Value™ of ARS61.70.
GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.
Key valuation signals for BUE:ROSE:
EBITDA Margin %: 9.24% (18% above median its 10-year median of 7.84)
GF Value™: ARS61.70 vs. price of ARS160.50 (160.1% above fair value)
Industry Position: 25.7% below the Drug Manufacturers median (#840 of 955)
No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
39GF Score
Get the complete analysis for BUE:ROSE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:ROSE has been successfully added to your 
